TNFα blockade in checkpoint inhibition: The good, the bad, or the ugly? Editorial

  


Authors: Weber, J. S.; Postow, M. A.
Title: TNFα blockade in checkpoint inhibition: The good, the bad, or the ugly?
Abstract: The impact on survival of steroids and TNFα blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNFα-blocking antibodies such as infliximab.See related article by Verheijden et al., p. 2268. ©2020 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 26
Issue: 9
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2020-05-01
Start Page: 2085
End Page: 2086
Language: English
DOI: 10.1158/1078-0432.Ccr-20-0387
PUBMED: 32102949
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084961524&doi=10.1158%2f1078-0432.CCR-20-0387&partnerID=40&md5=109e98ee306673851b27345e78966417
Notes: Note -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    361 Postow
Related MSK Work